Brief: U.S. FDA Places Jubilant Pharmova Facility Under Import Alert At Roorkee
July 15 (Reuters) - Jubilant Pharmova Ltd JUBA.NS :
* USFDA HAS PLACED FACILITY UNDER IMPORT ALERT AT ROORKEE
* PRODUCTS THAT GET IMPACTED DUE TO IMPORT ALERT CONTRIBUTED
TO
LESS THAN 3% OF FY21 TOTAL REVENUES
* IMPORT ALERT IN RESPONSE TO FDA INSPECTION CONDUCTED AT
DOSAGE
FORMULATIONS FACILITY AT ROORKEE DURING MARCH 2021
* FDA HAS EXEMPTED CERTAIN PRODUCTS INCLUDING VALSARTAN
TABLETS
FROM IMPORT ALERT
Source text for Eikon: ID:nBSEVLFWj
Further company coverage: JUBA.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures